User profiles for M. Rudek
Michelle RudekProfessor of Oncology and Medicine, Johns Hopkins University Verified email at jhmi.edu Cited by 13354 |
The rising challenge of non–AIDS-defining cancers in HIV-infected patients
…, MA Rudek, C Okuliar, M Young… - Clinical infectious …, 2012 - academic.oup.com
Since the advent of HAART, patients with HIV infection have seen a significant improvement
in their morbidity, mortality, and life expectancy. The incidence of AIDS-defining illnesses, …
in their morbidity, mortality, and life expectancy. The incidence of AIDS-defining illnesses, …
Entinostat: a promising treatment option for patients with advanced breast cancer
Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which
potently and selectively inhibits class I and IV HDAC enzymes. This action promotes histone …
potently and selectively inhibits class I and IV HDAC enzymes. This action promotes histone …
Use of antineoplastic agents in patients with cancer who have HIV/AIDS
MA Rudek, C Flexner, RF Ambinder - The lancet oncology, 2011 - thelancet.com
Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and
mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-…
mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-…
Combination epigenetic therapy has efficacy in patients with refractory advanced non–small cell lung cancer
…, N Franco, B Lee, S Tsai, IE Delgado, MA Rudek… - Cancer …, 2011 - aacrjournals.org
Epigenetic alterations are strongly associated with the development of cancer. We conducted
a phase I/II trial of combined epigenetic therapy with azacitidine and entinostat, inhibitors …
a phase I/II trial of combined epigenetic therapy with azacitidine and entinostat, inhibitors …
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
…, O Galm, T Dauses, JE Karp, MA Rudek, M Zhao… - Cancer …, 2006 - aacrjournals.org
… from 25 to 75 mg/m 2 /d; the mean ± SD C max and AUC 0-8 at 25 mg/m 2 /d were 1,612 ±
1,042 nmol/L and 1,941 ± 980 h × nmol/L, respectively, and at 75 mg/m 2 /d was 6,207 nmol/L …
1,042 nmol/L and 1,941 ± 980 h × nmol/L, respectively, and at 75 mg/m 2 /d was 6,207 nmol/L …
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
…, ML Alattar, MR Grunwald, MA Rudek… - Blood, The Journal …, 2013 - ashpublications.org
Patients received 5-azacytidine (AZA) 75 mg/m 2 intravenously daily for 7 days and sorafenib
400 mg orally twice daily continuously; cycles were repeated at ∼1-month intervals. Forty-…
400 mg orally twice daily continuously; cycles were repeated at ∼1-month intervals. Forty-…
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance
…, H Dekker, RJ Honeywell, MA Rudek… - Clinical Cancer …, 2011 - aacrjournals.org
Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an
important clinical problem, but its underlying mechanisms are largely unknown. We analyzed …
important clinical problem, but its underlying mechanisms are largely unknown. We analyzed …
A targeting modality for destruction of RNA polymerase I that possesses anticancer activity
…, HM Moore, B Bai, MA Rudek, CJ Bieberich, M Laiho - Cancer cell, 2014 - cell.com
We define the activity and mechanisms of action of a small molecule lead compound for
cancer targeting. We show that the compound, BMH-21, has wide and potent antitumorigenic …
cancer targeting. We show that the compound, BMH-21, has wide and potent antitumorigenic …
[HTML][HTML] Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute …
The fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation is associated
with a high relapse rate for patients with acute myeloid leukemia (AML) even after …
with a high relapse rate for patients with acute myeloid leukemia (AML) even after …
Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer
Curcumin or diferuloylmethane is a yellow polyphenol extracted from the rhizome of turmeric
(Curcuma longa). A large volume (several hundreds) of published reports has established …
(Curcuma longa). A large volume (several hundreds) of published reports has established …